Resistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations

Antiviral Therapy

Volumn 11, Issue 7, 2006, Pages 847-855

  Courcambeck, Jérôme ^a   Bouzidi, Mourad ^a   Perbost, Régis ^a   Jouirou, Besma ^a   Amrani, Nolwenn ^a   Cacoub, Patrice ^b   Pèpe, Gérard ^c   Sabatier, Jean Marc ^d   Halfon, Philippe ^a  

^a Genoscience   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CNRS   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CILUPREVIR; MONTIRELIN; PROTEINASE INHIBITOR;

ARTICLE; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG INHIBITION; DRUG STRUCTURE; GENE MUTATION; HEPATITIS C VIRUS; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS IDENTIFICATION; VIRUS RESISTANCE;

BINDING SITES; CARBAMATES; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; POINT MUTATION; QUINOLINES; SERINE ENDOPEPTIDASES; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33750947650     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Ascione A, De Luca M, Di Costanzo GG, et al. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. Curr Pharm Des 2002; 8:977-980.
5. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
6. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20:577-582.
7. Lebray P, Nalpas B, Vallet-Pichard A, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther 2005; 10:769-776.
8. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 1995; 69:7519-7528.
9. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999; 7:1353-1363.
10. De Francesco R, Steinkuhler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol 2000; 242:149-169.
11. Gale M, Jr., Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-945.
12. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102:2992-2997.
13. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-1172.
14. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-1148.
15. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-189.
16. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280:36784-36791.
17. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514.
18. Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006 281:8205-8215.
19. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005; 21:343-357.
20. Deval J, Courcambeck J, Selmi B, Boretto J, Canard B. Structural determinants and molecular mechanisms for the resistance of HIV-1 RT to nucleoside analogues. Curr Drug Metab 2004; 5:305-316.
21. Turner D, Schapiro JM, Brenner BG, Wainberg MA. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther 2004; 9:301-314.
22. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9:149-160.
23. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431.
24. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633.
25. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26:29-37.
26. Stranska R, van Loon AM, Bredius RG, et al. Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child. Antivir Ther 2004; 9:97-104.
27. Thomsen DR, Oien NL, Hopkins TA, et al. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J Virol 2003; 77:1868-1876.
28. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436:953-960.
29. Dalmau D, Klimkait T, Telenti A. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration. Antivir Ther 2005; 10:867-872.
30. Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77:3669-3679.
31. Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003; 278:49164-49170.
32. Nguyen TT, Gates AT, Gutshall LL, et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother 2003; 47:3525-3530.
33. Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48:2260-2266.
34. Courcambeck J, Perbost R, Chabaud P, et al. Molecular mechanism susceptibility profile of BILN-2061 to various hepatitis C virus genotypes and NS3-NS4A protease mutations: D168A and D168V. 55th Annual Meeting of the American Association for the Study of Liver Diseases. 29 October-2 November 2004. Abstract 513.
35. Di Marco S, Rizzi M, Volpari C, et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000; 275:7152-7157.
36. Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004; 78:7352-7359.
37. Pepe G, Guiliani G, Loustalet S, Halfon P. Hydration free energy a fragmental model and drug design. Eur J Med Chem 2002; 37:865-872.
38. Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-516.
39. Pepe G, Seres B, Laporte D, Del Re C. Surface electrostatic potentials on macromolecules in a monopole approximation: A computer program and an application to cytochromes. J Theor Biol 1985; 115:571-593.
40. Pepe G, Siri D. GENMOL. A fast program for molecular modeling. Application to the determination of the psychotonic or sedative effect of tricyclic antidepressant drugs. Stud Phys Theor Chem 1990; 71:93-101.
41. Yan Y, Li Y, Munshi S, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998; 7:837-847.
42. Tsantrizos YS, Bolger G, Bonneau P, et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl 2003; 42:1356-1360.
43. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26:283-291.
44. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000; 300:403-418.
45. Sarafianos SG, Das K, Clark AD, Jr, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999; 96:10027-10032.
46. Courcambeck J, Perbost R, Chabaud P, et al. Molecular susceptibility profil of BILN-2061 for common HCV genotypes and NS3-NS4A protease resistance mutations: D168A and D168V. Gastroenterol Clin Biol 2004; 28:768.
47. Deval J, Navarro JM, Selmi B, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004; 279:25489-25496.
48. Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006.
49. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18:2714-2723.